Daniel A Pollyea

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 39

Top Topics

Acute Myeloid Leukemia

Newly Diagnosed

Drug Administration

Monoclonal Antibody

Top Venues

Cancer discovery

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Hartmut Döhner, Keith W Pratz, Courtney D D DiNardo, Andrew H Wei, Brian A Jonas, Vinod Pullarkat, Michael J Thirman, Christian Recher, Andre C Schuh, Sunil Babu, Xiaotong Li, Grace Ku, Zihuan Liu, Yan Sun, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A Pollyea
Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine. Blood (2024)
Anagha Inguva Sheth, Mark J Althoff, Hunter Tolison, Krysta Engel, Maria L Amaya, Anna E Krug, Tracy N Young, Mohammad Minhajuddin, Shanshan Pei, Sweta B Patel, Amanda C Winters, Regan Miller, Ian T Shelton, Jonathan R St-Germain, Tianyi Ling, Courtney L Jones, Brian Raught, Austin E Gillen, Monica Ransom, Sarah Staggs, Clayton A Smith, Daniel A Pollyea, Brett M Stevens, Craig T Jordan
Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium. Cancer discovery (2024)
Anagha Inguva Sheth, Mark J Althoff, Hunter Tolison, Krysta Engel, Maria L Amaya, Anna E Krug, Tracy N Young, Mohammad Minhajuddin, Shanshan Pei, Sweta B Patel, Amanda C Winters, Regan Miller, Ian T Shelton, Jonathan R St-Germain, Tianyi Ling, Courtney L Jones, Brian Raught, Austin E Gillen, Monica Ransom, Sarah Staggs, Clayton A Smith, Daniel A Pollyea, Brett M Stevens, Craig T Jordan
Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium. Cancer discovery (2024)
Jennifer Marvin-Peek, Jason S Gilbert, Daniel A Pollyea, Courtney D D DiNardo
Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go? American journal of hematology (2024)
Kellen B Gil, Diana Abbott, Maria L Amaya, Marc Schwartz, Jonathan A Gutman, Andrew Kent, Grace Bosma, Daniel A Pollyea, Christine M McMahon
Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia. Leukemia & lymphoma (2024)
Jennifer Marvin-Peek, Jason S Gilbert, Daniel A Pollyea, Courtney D D DiNardo
Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go? American journal of hematology 99 (9) (2024)
David A Sallman, Monzr M Al Malki, Adam S Asch, Eunice S Wang, Joseph G Jurcic, Terrence J Bradley, Ian W Flinn, Daniel A Pollyea, Suman Kambhampati, Tiffany N Tanaka, Joshua F Zeidner, Guillermo Garcia Manero, Deepa Jeyakumar, Rami S Komrokji, Jeffrey Lancet, Hagop M Kantarjian, Lin Gu, Yajia Zhang, Anderson Tan, Mark Chao, Carol O'Hear, Giridharan Ramsingh, Indu Lal, Paresh Vyas, Naval G Daver
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
David A Sallman, Monzr M Al Malki, Adam S Asch, Eunice S Wang, Joseph G Jurcic, Terrence J Bradley, Ian W Flinn, Daniel A Pollyea, Suman Kambhampati, Tiffany N Tanaka, Joshua F Zeidner, Guillermo Garcia Manero, Deepa Jeyakumar, Rami S Komrokji, Jeffrey Lancet, Hagop M Kantarjian, Lin Gu, Yajia Zhang, Anderson Tan, Mark Chao, Carol O'Hear, Giridharan Ramsingh, Indu Lal, Paresh Vyas, Naval G Daver
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Shanshan Pei, Ian T Shelton, Austin E Gillen, Brett M Stevens, Maura Gasparetto, Yanan Wang, Lina Liu, Jun Liu, Tonya M Brunetti, Krysta Engel, Sarah Staggs, William Showers, Anagha Inguva Sheth, Maria L Amaya, Mohammad Minhajuddin, Amanda C Winters, Sweta B Patel, Hunter Tolison, Anna E Krug, Tracy N Young, Jeffrey Schowinsky, Christine M McMahon, Clayton A Smith, Daniel A Pollyea, Craig T Jordan
A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. Cancer discovery (2023)
Anagha Inguva Sheth, Krysta Engel, Hunter Tolison, Mark J Althoff, Maria L Amaya, Anna Krug, Tracy Young, Shanshan Pei, Sweta B Patel, Mohammad Minhajuddin, Amanda Winters, Regan Miller, Ian Shelton, Jonathan St-Germain, Tianyi Ling, Courtney Jones, Brian Raught, Austin E Gillen, Monica Ransom, Sarah Staggs, Clayton A Smith, Daniel A Pollyea, Brett M Stevens, Craig T Jordan
Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium. bioRxiv : the preprint server for biology (2023)
Andrew Kent, Daniel A Pollyea
Top advances of the year: Leukemia. Cancer 129 (7) (2022)
Daniel A Pollyea
Professional Courtesy. Annals of internal medicine 175 (6) (2022)
Andrew Kent, Daniel A Pollyea
Top advances of the year: Leukemia. Cancer (2022)
Mark A Dawson, Gautam Borthakur, Brian James Patrick Huntly, Anastasios Karadimitris, Adrian Alegre, Aristeidis Chaidos, Dan T Vogl, Daniel A Pollyea, Faith E Davies, Gareth J Morgan, Jacob Lowell Glass, Manali Kamdar, Maria-Victoria Mateos-Manteca, Natalia Tovar, Paul Yeh, Regina García Delgado, Faisal Basheer, Ludovica Marando, Paolo Gallipoli, Anastasia Wyce, Anu Shilpa Krishnatry, Olena Barbash, Evi Bakirtzi, Geraldine Ferron-Brady, Natalie O Karpinich, Michael T McCabe, Shawn W Foley, Thierry Horner, Arindam Dhar, Brandon E Kremer, Michael J Dickinson
A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Daniel A Pollyea, Keith W Pratz, Andrew H Wei, Vinod A Pullarkat, Brian A Jonas, Christian Recher, Sunil Babu, Andre C Schuh, Monique Dail, Yan Sun, Jalaja Potluri, Brenda J Chyla, Courtney D D DiNardo
Outcomes in Patients With Poor-risk Cytogenetics With or Without TP53 Mutations Treated With Venetoclax and Azacitidine. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Andrew Kent, Daniel A Pollyea
Top advances of the year: Leukemia. Cancer 129 (7) (2022)
Daniel A Pollyea, Courtney D D DiNardo, Martha L Arellano, Arnaud Pigneux, Walter Fiedler, Marina Konopleva, David A Rizzieri, B Douglas Smith, Atsushi Shinagawa, Roberto M Lemoli, Monique Dail, Yinghui Duan, Brenda J Chyla, Jalaja Potluri, Catherine L Miller, Hagop M Kantarjian
Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (13) (2022)
Naval G Daver, Monique Dail, Jacqueline S Garcia, Brian A Jonas, Karen W L Yee, Kevin R Kelly, Norbert Vey, Sarit Assouline, Gail J Roboz, Stefania Paolini, Daniel A Pollyea, Agostino Tafuri, Joseph M Brandwein, Arnaud Pigneux, Bayard L Powell, Pierre Fenaux, Rebecca L Olin, Giuseppe Visani, Giovanni Martinelli, Maika Onishi, Jue Wang, Weize Huang, Cherie Green, Marion G Ott, Wan-Jen Hong, Marina Y Konopleva, Michael Andreeff
Venetoclax and idasanutlin in relapsed/refractory AML: a non-randomized, open-label phase 1b trial. Blood (2022)
Andrew Kent, Daniel A Pollyea
Top advances of the year: Leukemia. Cancer 129 (7) (2022)
Courtney D D DiNardo, Daniel A Pollyea
Beyond Survival: The US Food and Drug Administration Confirms Surrogate End Points for Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (8) (2022)
Aaron T Gerds, Bart L Scott, Peter Greenberg, Tara L Lin, Daniel A Pollyea, Amit K Verma, Monique Dail, Yuning Feng, Cherie Green, Connie Ma, Bruno C Medeiros, Mark Yan, Kasra Yousefi, William Donnellan
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome. Blood advances 6 (4) (2022)
Daniel A Pollyea, John Barrett, Courtney D D DiNardo, Laura C Michaelis, Gail J Roboz, Robert Q Le, Kelly J Norsworthy, R Angelo de Claro, Marc R Theoret, Richard Pazdur
Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Evan Cherry, Diana Abbott, Maria L Amaya, Christine McMahon, Marc Schwartz, Julie Rosser, Audrey Sato, Jeffrey T Schowinsky, Anagha Inguva, Mohd Minhajuddin, Shanshan Pei, Brett M Stevens, Amanda C Winters, Craig T Jordan, Clayton Smith, Jonathan A Gutman, Daniel A Pollyea
Venetoclax and Azacitidine Compared to Induction Chemotherapy for Newly Diagnosed Patients with Acute Myeloid Leukemia. Blood advances (2021)
Fei Yang, Nicola Long, Tauangtham Anekpuritanang, Daniel Bottomly, Jonathan C Savage, Tiffany Lee, Jose M Solis-Ruiz, Uma Borate, Beth Wilmot, Cristina E Tognon, Allison M Bock, Daniel A Pollyea, Saikripa Mangala Radhakrishnan, Srinidhi Radhakrishnan, Prapti Arvind Patel, Robert H Collins, Srinivas K Tantravahi, Michael W Deininger, Guang Fan, Brian J Druker, Ujwal Shinde, Jeffrey W Tyner, Richard D Press, Shannon K McWeeney, Anupriya Agarwal
Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult AML patients. Blood (2021)
Maria L Amaya, Anagha Inguva, Shanshan Pei, Courtney L Jones, Anna Krug, Haobin Ye, Mohammad Minhajuddin, Amanda C Winters, Steffanie L Furtek, Fabia Gamboni, Brett M Stevens, Angelo D'Alessandro, Daniel A Pollyea, Philip Reigan, Craig T Jordan
The STAT3-MYC Axis Promotes Survival of Leukemia Stem Cells by Regulating SLC1A5 and Oxidative Phosphorylation. Blood (2021)
Nicholas James Short, Martin S Tallman, Daniel A Pollyea, Farhad Ravandi, Hagop Kantarjian
Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (23) (2021)
Haobin Ye, Mohammad Minhajuddin, Anna Krug, Shanshan Pei, Chih-Hsing Chou, Rachel Culp-Hill, Jessica Ponder, Erik De Bloois, Björn Schniedewind, Maria L Amaya, Anagha Inguva, Brett M Stevens, Daniel A Pollyea, Uwe Christians, H Leighton Grimes, Angelo D'Alessandro, Craig T Jordan
The Hepatic Microenvironment Uniquely Protects Leukemia Cells through Induction of Growth and Survival Pathways Mediated by LIPG. Cancer discovery 11 (2) (2020)
Shanshan Pei, Daniel A Pollyea, Annika Gustafson, Brett M Stevens, Mohammad Minhajuddin, Rui Fu, Kent A Riemondy, Austin E Gillen, Ryan M Sheridan, Jihye Kim, James C Costello, Maria L Amaya, Anagha Inguva, Amanda C Winters, Haobin Ye, Anna Krug, Courtney L Jones, Biniam Adane, Nabilah Khan, Jessica Ponder, Jeffrey Schowinsky, Diana Abbott, Andrew Hammes, Jason R Myers, John M Ashton, Travis Nemkov, Angelo D'Alessandro, Jonathan A Gutman, Haley E Ramsey, Michael R Savona, Clayton A Smith, Craig T Jordan
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Cancer discovery 10 (4) (2020)
Daniel A Pollyea, Tracy I George, Mehrdad Abedi, Rafael Bejar, Christopher R Cogle, Kathryn Foucar, Guillermo Garcia-Manero, David L Grinblatt, Rami S Komrokji, Jaroslaw P Maciejewski, Dennis A Revicki, Gail J Roboz, Michael R Savona, Bart L Scott, Mikkael A Sekeres, Michael A Thompson, Sandra E Kurtin, Chrystal U Louis, Melissa Nifenecker, E Dawn Flick, Arlene S Swern, Pavel Kiselev, David P Steensma, Harry P Erba
Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect ® MDS/AML Disease Registry. EJHaem 1 (1) (2020)
Daniel A Pollyea, Keith Pratz, Anthony Letai, Brian A Jonas, Andrew H Wei, Vinod A Pullarkat, Marina Y Konopleva, Michael J Thirman, Martha Arellano, Pamela S Becker, Brenda Chyla, Wan-Jen Hong, Qi Jiang, Jalaja Potluri, Courtney D D DiNardo
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. American journal of hematology 96 (2) (2020)
Pau Montesinos, Gail J Roboz, Claude-Eric Bulabois, Marion Subklewe, Uwe Platzbecker, Yishai Ofran, Cristina Papayannidis, Agnieszka Wierzbowska, Ho Jin Shin, Vadim Doronin, Stefan Deneberg, Su-Peng Yeh, Mehmet Ali Ozcan, Steven Knapper, Jorge Cortes, Daniel A Pollyea, Gert Ossenkoppele, Sergio A Giralt, Hartmut Döhner, Michael Heuser, Liang Xiu, Indrajeet Singh, Fei Huang, Julie S Larsen, Andrew H Wei
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia 35 (1) (2020)
Haijiao Zhang, Beth Wilmot, Daniel Bottomly, Kim-Hien T Dao, Emily Stevens, Christopher A Eide, Vishesh Khanna, Angela Rofelty, Samantha Savage, Anna Reister Schultz, Nicola Long, Libbey White, Amy Carlos, Rachel Henson, Chenwei Lin, Robert Searles, Robert H Collins, Daniel J DeAngelo, Michael W Deininger, Tamara Dunn, Than Hein, Marlise R Luskin, Bruno C Medeiros, Stephen T Oh, Daniel A Pollyea, David P Steensma, Richard M Stone, Brian J Druker, Shannon K McWeeney, Julia E Maxson, Jason R Gotlib, Jeffrey W Tyner
Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood 134 (11) (2019)
Daniel A Pollyea
Acute myeloid leukemia drug development in the post-venetoclax era. American journal of hematology 94 (9) (2019)
Courtney L Jones, Brett M Stevens, Angelo D'Alessandro, Rachel Culp-Hill, Julie A Reisz, Shanshan Pei, Annika Gustafson, Nabilah Khan, James DeGregori, Daniel A Pollyea, Craig T Jordan
Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II. Blood 134 (4) (2019)
Daniel A Pollyea, Martin S Tallman, Stéphane de Botton, Hagop M Kantarjian, Robert H Collins, Anthony S Stein, Mark G Frattini, Qiang Xu, Alessandra Tosolini, Wendy L See, Kyle J MacBeth, Samuel V Agresta, Eyal C Attar, Courtney D D DiNardo, Eytan M Stein
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia 33 (11) (2019)
Brian A Jonas, Daniel A Pollyea
How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia 33 (12) (2019)
Daniel A Pollyea, Brett M Stevens, Courtney L Jones, Amanda Winters, Shanshan Pei, Mohammad Minhajuddin, Angelo D'Alessandro, Rachel Culp-Hill, Kent A Riemondy, Austin E Gillen, Jay R Hesselberth, Diana Abbott, Derek Schatz, Jonathan A Gutman, Enkhtsetseg Purev, Clayton Smith, Craig T Jordan
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nature medicine 24 (12) (2018)
Brett M Stevens, Nabilah Khan, Angelo D'Alessandro, Travis Nemkov, Amanda Winters, Courtney L Jones, Wei Zhang, Daniel A Pollyea, Craig T Jordan
Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes. Nature communications 9 (1) (2018)
Jorge E Cortes, Florian H Heidel, Andrzej Hellmann, Walter Fiedler, B Douglas Smith, Tadeusz Robak, Pau Montesinos, Daniel A Pollyea, Pierre DesJardins, Oliver Ottmann, Weidong Wendy Ma, M Naveed Shaik, A Douglas Laird, Mirjana Zeremski, Ashleigh O'Connell, Geoffrey Chan, Michael Heuser
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia 33 (2) (2018)